|Articles|March 1, 2016
- Pharmaceutical Executive-03-01-2016
- Volume 36
- Issue 3
Pharmaceutical Executive, March 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive March 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 10 years ago
Beyond 2020: Building Strategic Coherence in the New Health Economyover 10 years ago
What Errors Do We Miss in Clinical Trials?over 10 years ago
Data Disclosure: Sealing the Error Envelopeover 10 years ago
Vaccines 2016: Big Bets for Global Threatsover 10 years ago
Drug Delivery Roundtable: More than the Pillover 10 years ago
Orphans of the Stormover 10 years ago
Country Report: The NetherlandsAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Significance of FDA’s First Warning Letter for Inappropriate Use of AI
2
Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion
3
Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance
4
M&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo
5